title: The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis.
abstract: BACKGROUND
  Erectile dysfunction (ED) is frequently observed in end-stage renal disease (ESRD) patients on hemodialysis (HD) compared to non-uremic patients. This situation causes severe psychogenic problems in patients and disrupts the quality of life. Different phosphodiesterase type 5 (PDE-5) inhibitors have been used, and efficacies revealed, for the treatment of ED in HD patients; however, there are no studies related to udenafil use or results for HD patients. This study retrospectively evaluated the efficacy and reliability of udenafil for HD patients.
  
  
  METHODS
  The laboratory findings, side effects after treatment, and International Index of Erectile Function (IIEF) scores before and after treatment were compared and evaluated for HD patients who applied to our urology clinic with ED complaints and were treated with udenafil.
  
  
  RESULTS
  The results showed that in the HD patient group with ED, apart from ED, there were severe rates of other sexual dysfunction. In our patient group, there was a statistically significant improvement in all scores for erectile function (p = 0.033), orgasmic function (p < 0.001), sexual desire (p < 0.001), relationship satisfaction (p < 0.001), and general satisfaction (p < 0.001) after treatment. The reported side effects were headache in one patient and dyspepsia in one patient.
  
  
  CONCLUSIONS
  We concluded that udenafil is an effective and reliable treatment approach for HD patients; however, our results require support from prospective randomized crossover studies with sildenafil.
authors.affiliation: a Department of Urology , Samsun Training and Research Hospital , Samsun , Turkey ;
authors.forename: Lokman
authors.initials: L
authors.lastname: Irkilata
authors.affiliation: b Department of Urology, Medical Faculty, Recep Tayyip Erdogan University , Rize , Turkey ;
authors.forename: Hasan Riza
authors.initials: HR
authors.lastname: Aydin
authors.affiliation: c Department of Nephrology , Samsun Training and Research Hospital , Samsun , Turkey.
authors.forename: Ismail
authors.initials: I
authors.lastname: Ozer
authors.affiliation: a Department of Urology , Samsun Training and Research Hospital , Samsun , Turkey ;
authors.forename: Mustafa
authors.initials: M
authors.lastname: Aydin
authors.affiliation: a Department of Urology , Samsun Training and Research Hospital , Samsun , Turkey ;
authors.forename: Hüseyin Cihan
authors.initials: HC
authors.lastname: Demirel
authors.affiliation: a Department of Urology , Samsun Training and Research Hospital , Samsun , Turkey ;
authors.forename: Caner
authors.initials: C
authors.lastname: Moral
authors.affiliation: a Department of Urology , Samsun Training and Research Hospital , Samsun , Turkey ;
authors.forename: Mustafa Kemal
authors.initials: MK
authors.lastname: Atilla
mesh_terms: D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects*; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D006435:Renal Dialysis / Q000009:adverse effects*; D015203:Reproducibility of Results; D012189:Retrospective Studies; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D000096926:Benzenesulfonamides
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C419664:udenafil; D000096926:Benzenesulfonamides
keywords: Kidney failure; chronic; erectile dysfunction; physiological; renal dialysis; sexual dysfunction; udenafil